Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-Year outcomes - Abstract

Objectives: To assess the treatment outcomes of a single session of whole gland high intensity focused ultrasound (HIFU) for patients with localized prostate cancer (PCa).

Methods: Response rates were defined using the Stuttgart and Phoenix criteria. Complications were graded according to the Clavien score.

Results: At a median follow-up of 94months, 48 (44.4%) and 50 (46.3%) patients experienced biochemical recurrence for Phoenix and Stuttgart definition, respectively. The 5- and 10-year actuarial biochemical recurrence free survival rates were 57% and 40%, respectively. The 10-year overall survival rate, cancer specific survival rate, and metastasis free survival rate were 72%, 90%, and 70%, respectively. Preoperative high risk category, Gleason score, preoperative PSA, and postoperative nadir PSA were independent predictors of oncological failure. 24.5% of patients had self-resolving LUTS, 18.2% had urinary tract infection, and 18.2% had acute urinary retention. A grade 3b complication occurred in 27 patients. Pad-free continence rate was 87.9% and the erectile dysfunction rate was 30.8%.

Conclusion: Single session HIFU can be alternative therapy for patients with low risk PCa. Patients with intermediate risk should be informed about the need of multiple sessions of HIFU and/or adjuvant treatments and HIFU performed very poorly in high risk patients.

Written by:
Limani K, Aoun F, Holz S, Paesmans M, Peltier A, van Velthoven R.   Are you the author?
Department of Urology, Jules Bordet Institute, 1 Rue Héger-Bordet, 1000 Brussels, Belgium; Université Libre de Bruxelles, 50 Franklin Roosevelt Avenue, 1050 Brussels, Belgium; Department of Data Management, Jules Bordet Institute, 1 Rue Héger-Bordet, 1000 Brussels, Belgium.

Reference: Prostate Cancer. 2014;2014:186782.
doi: 10.1155/2014/186782

PubMed Abstract
PMID: 25045541 Prostate Cancer Section